Human Nanog Homeobox Protein ELISA Kit
- Known as:
- Human Nanog Homeobox Protein Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- E14436h
- Product Quantity:
- 96T
- Category:
- Peptides
- Supplier:
- EIAab
- Gene target:
- Human Nanog Homeobox Protein ELISA Kit
Related genes to: Human Nanog Homeobox Protein ELISA Kit
- Gene:
- NANOG NIH gene
- Name:
- Nanog homeobox
- Previous symbol:
- -
- Synonyms:
- FLJ12581, FLJ40451
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 2003-09-10
- Date modifiied:
- 2014-11-19
Related products to: Human Nanog Homeobox Protein ELISA Kit
Related articles to: Human Nanog Homeobox Protein ELISA Kit
- Zinc finger PBX1-interacting protein (Zfp462/Zfpip), a vertebrate-specific C2H2-type transcription factor, plays an essential role in early embryogenesis and the maintenance of embryonic stem cell (ESC) pluripotency. While previous studies have largely focused on its repressive functions, its potential role in transcriptional activation has remained unclear. In this study, we demonstrate that Zfp462 knockout (KO) impairs ESC self-renewal and disrupts the expression of pluripotency-associated and developmental genes. Luciferase reporter assays showed that Zfp462 overexpression increased (also known as ) promoter activity, whereas Zfp462 KO reduced its activity, supporting a role for Zfp462 in transcriptional activation. Integrative multiomics analyses reveal that Zfp462 is functionally integrated into the ESC core pluripotency module and cooperates with Oct4, Sox2, and Nanog to activate pluripotency-associated genes. Together, these findings reveal a critical role for Zfp462 in ESC pluripotency and establish it as a novel regulator within the pluripotency gene regulatory network. - Source: PubMed
Publication date: 2026/09/18
Yu MengYang YiChen ChunlinWang JiaqiYang WubinYang RanXu YixiaoWang FengshengZhang ChenZhang YangkaiDong YutongWang JiangjunXue RuoyiTian YanpingCui XiaopingRuan YanLi HongliZhang JunleiJian Rui - Prostate cancer is aggressive in dogs and characterized by limited therapeutic responsiveness and a poor prognosis. While cancer stem cells (CSCs) are increasingly recognized as key drivers of tumour progression, therapeutic resistance and metastasis in human prostate cancer, their role in canine prostate cancer remains poorly defined. This study aimed to characterize the expression of stem cell-associated markers in canine prostatic adenocarcinoma by assessing a broad panel of CSC-associated markers in primary prostate tissues. Immunohistochemistry evaluated the expression and subcellular localization of seven CSC-associated markers (CD44, CD133, Nanog, Nestin, Oct3/4, Sox2 and Trop2) in non-neoplastic canine prostate samples and prostatic adenocarcinoma cases. Marker expression was semiquantitatively assessed and differences between groups analysed using non-parametric statistical tests. Neoplastic prostatic tissue demonstrated significantly increased immunolabelling of CD44, CD133, Nanog (nuclear and cytoplasmic), Nestin (nuclear and cytoplasmic), Oct3/4 (cytoplasmic), Sox2 (cytoplasmic) and Trop2 compared with non-neoplastic prostate tissue (P <0.05). In contrast, nuclear Oct3/4 and nuclear Sox2 immunolabelling did not differ significantly between groups. Distinct patterns of nuclear and cytoplasmic localization were observed for several markers, suggesting context-dependent regulation and potential functional heterogeneity within CSC-like populations. These findings demonstrate that canine prostatic adenocarcinomas have multiple stem cell-associated markers, consistent with the presence of a stemness-associated phenotype within these tumours. - Source: PubMed
Publication date: 2026/09/17
Story Michelle MFonseca-Alves Carlos ELaufer-Amorim ReneePalmieri Chiara - Resistance to chemo/radio therapy, along with recurrence of aggressive tumors, is a major factor contributing to cervical cancer (CaCx) mortality. This is largely driven by a small subset of slow-growing cancer stem cells (CSC). The present study aimed to explore the potential of psoralidin to target CaCx-CSC. Molecular docking (MD) and MD simulation was conducted to analyze the interaction of psoralidin with core stemness markers Oct4, Sox2, and Nanog and stability of interaction, respectively. A low-adhesive culture system was established to enrich CSC, which were then treated with the IC concentration of psoralidin to study anti-CSC effect. Psoralidin demonstrated strong binding to stemness markers, cell permeability, and no predicted hepatotoxicity in silico. Binding stability was highest with Oct4, followed by Nanog and Sox2. IC values of 3-4 µM were observed across CaCx cell lines C33a, SiHa, and HeLa regardless of HPV status. Cervical-CSC enriched under low-adhesion conditions displayed elevated stemness marker expression, confirmed by qRT-PCR and immunoblotting. Psoralidin-treated cervicospheres showed reduced spheroid size, number, and structural integrity. Treatment also downregulated stemness markers as well as NF-κB p65, c-Rel, and pSTAT3. Overall, our preclinical findings demonstrate the potential of psoralidin to target CCSC and provide a strong rationale for its further translational evaluation as an adjuvant to existing therapeutic regimens in cervical cancer. - Source: PubMed
Publication date: 2026/09/16
Tripathi TanyaKumar ShivamJoshi UditChaudhary ApoorvaJanjua DivyaTanwar NehaMittal AasthaSenrung AnnaBharti Alok Chandra - Primary effusion lymphoma (PEL) is a B cell lymphoma that occurs most often in people living with HIV/AIDS and is caused by Kaposi sarcoma herpesvirus (KSHV). Most are also infected with Epstein-Barr virus (EBV). While newer regimens now exist, PEL still has poorer outcomes compared to other HIV-associated lymphomas. Since PEL B cells lack typical B cell markers, we aim to identify other surface proteins in disease cells that may act as possible diagnostic or prognostic markers. We performed single cell DNA-seq and antibody derived tag-seq on BCBL1 (KSHV+/EBV-) and LCL (KSHV-/EBV+ lymphoblastoid cell line) cells to determine which surface markers are specific for KSHV+ PEL. We identified neuropilin-1 (NRP1) as a surface marker that is overexpressed in KSHV+ PEL cell lines (BCBL1, JSC1), but not in EBV+ LCL cells. NRP1 depletion during reactivation reduced lytic transcription, virion production, and infectivity of NRP1+ PEL cell lines. Selected NRP1+ PEL cells also expressed higher levels of and compared to controls. NRP1+ PEL cells had higher amounts of lytic transcripts. Conversely, lytic cells express higher amounts of NRP1 transcripts at the single-cell level. Overexpression of NRP1 resulted in significantly higher lytic transcripts during lytic induction. Our findings suggest that NRP1 is a surface marker expressed for a subtype of PEL cells that is required for efficient lytic replication. It is also associated with increased expression of stemness markers, denoting poor prognosis in cancer.IMPORTANCEKSHV is a cancer-causing herpesvirus that is the etiologic agent for primary effusion lymphoma (PEL), with half of patients who are chemotherapy-resistant and have poor prognosis overall. Here, we present our discovery of NRP1 as a surface marker for a proposed subtype of PEL cell lines. We present data that support a role for NRP1 in generating infectious progeny virions and that NRP1 is associated with viral gene expression during its lytic phase. Due to NRP1's role in cancer as studied by others, it is possible that NRP1 is contributing toward worse clinical outcomes in a subgroup of people with PEL. We propose that NRP1 is a potential prognostic marker for a certain category of PEL and can be targeted in chemotherapy-resistant PEL since small molecule inhibitors against NRP1 are already available. - Source: PubMed
Publication date: 2026/09/15
Serquina Anna K PLee JulieCho EricMahesh GuruswamyAfsari BahmanZiegelbauer Joseph M - Metastasis, chemoresistance, and tumour recurrence are facilitated by cancer stem cells (CSCs), a small subpopulation of cells capable of regenerating a primary tumour while maintaining the tumour's genetic and phenotypic features. CSCs can be identified by the expression of specific markers; however, the CSC population in ovarian clear cell carcinoma (OCCC), a rare histotype of ovarian cancer, remains poorly defined. Given the well-established role that CSCs play in cancer progression and metastasis, it is critical to identify reliable markers of CSCs in OCCC. Here, we endeavoured to determine whether ALDH1 expression could be used to define OCCC stem cells in OCCC cell lines using a variety of methods including assessing ALDH1A1 expression in spheroids generated under distinct conditions. We also generated and used chemo-resistant cell lines to assess the enrichment of cancer stem cells. Human OCCC cell lines were enriched for CSCs using selective culture conditions and drug resistance methods. CSC-enriched spheroids demonstrated increased expression of stemness markers NANOG and SOX2, while ALDH1A1 expression was enriched only in drug-resistant cell lines, relative to parental cell lines. RNA-seq analyses of CSC-media-derived spheroids versus standard media spheroids provided novel data supporting CSC enrichment and identified transcription factors induced by CSC media. These findings highlight the ambiguous role of ALDH1A1 as a CSC marker in OCCC and demonstrates the utility of CSC enrichment methods for identifying CSC populations in OCCC cell lines. - Source: PubMed
Publication date: 2026/08/22
Gebreyes BlaneKolendowski BartRamos-Valdes YudithShepherd Trevor GDiMattia Gabriel E